Share on StockTwits

ADMA Biologics (NASDAQ:ADMA) CEO Adam S. Grossman bought 2,100 shares of the company’s stock on the open market in a transaction that occurred on Thursday, August 14th. The stock was purchased at an average cost of $9.77 per share, for a total transaction of $20,517.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Maxim Group reiterated a “buy” rating on shares of ADMA Biologics in a research note on Friday, July 11th. They now have a $15.00 price target on the stock.

Shares of ADMA Biologics (NASDAQ:ADMA) traded up 0.51% during mid-day trading on Friday, hitting $9.80. 3,620 shares of the company’s stock traded hands. ADMA Biologics has a 52-week low of $6.52 and a 52-week high of $10.75. The stock’s 50-day moving average is $9.96 and its 200-day moving average is $8.81. The company’s market cap is $91.1 million.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.